Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments (terminated appraisal)

  • Technology appraisal
  • TA1112
  • Published: 

History

Documents created during the development process.

Notes